Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Association Of Brafv600e Mutation With The Aggressive Behavior Of Papillary Thyroid Microcarcinoma: A Meta-Analysis Of 33 Studies, Abdallah S. Attia, Mohammad Hussein, Peter P. Issa, Ahmad Elnahla, Ashraf Farhoud, Brandon M. Magazine, Mohanad R. Youssef, Mohamed Aboueisha, Mohamed Shama, Eman Toraih, Emad Kandil
Association Of Brafv600e Mutation With The Aggressive Behavior Of Papillary Thyroid Microcarcinoma: A Meta-Analysis Of 33 Studies, Abdallah S. Attia, Mohammad Hussein, Peter P. Issa, Ahmad Elnahla, Ashraf Farhoud, Brandon M. Magazine, Mohanad R. Youssef, Mohamed Aboueisha, Mohamed Shama, Eman Toraih, Emad Kandil
School of Medicine Faculty Publications
An association between the BRAFV600E mutation and the clinicopathological progression of papillary thyroid microcarcinoma (PTMC) has been suggested. We aimed to summarize the relevant literature and determine the predictive value of BRAFV600E mutation in predicting clinical outcomes and risk stratification in patients with PTMC. A systematic search using PubMed, Cochrane, and Embase up to February 2020 was performed. A total of 33 studies met the inclusion criteria, resulting in a pool of 8838 patients, of whom 5043 (57.1%) patients were positive for BRAFV600E mutation. Tumors with positive BRAFV600E mutation had a higher tendency for multifocality (RR = 1.09, 95%CI = …
Radiofrequency Ablation Of Indeterminate Thyroid Nodules: The First North American Comparative Analysis, Peter P. Issa, Mahmoud Omar, Chad P. Issa, Yusef Buti, Mohammad Hussein, Mohamed Aboueisha, Ali Abdelhady, Mohamed Shama, Grace S. Lee, Eman Toraih, Emad Kandil
Radiofrequency Ablation Of Indeterminate Thyroid Nodules: The First North American Comparative Analysis, Peter P. Issa, Mahmoud Omar, Chad P. Issa, Yusef Buti, Mohammad Hussein, Mohamed Aboueisha, Ali Abdelhady, Mohamed Shama, Grace S. Lee, Eman Toraih, Emad Kandil
School of Medicine Faculty Publications
Thyroid nodules can be classified as benign, malignant, or indeterminate, the latter of which make up 10–30% of nodules. Radiofrequency ablation (RFA) has become an attractive and promising therapy for the treatment of benign thyroid nodules. However, few studies have investigated the safety and efficacy of RFA for the management of indeterminate thyroid nodules. In this study, 178 patients with thyroid nodules diagnosed as benign (Bethesda II) or indeterminate (Bethesda III/IV) by preoperative cytopathological analysis were included. Patients in the benign and indeterminate cohorts had similar thyroid nodule volume reduction rates at 65.60% and 64.20%, respectively (p = 0.68). The …